Digel W, Porzsolt F, Schmid M, Herrmann F, Lesslauer W, Brockhaus M
Department of Internal Medicine III, University of Ulm, Federal Republic of Germany.
J Clin Invest. 1992 May;89(5):1690-3. doi: 10.1172/JCI115769.
The presence of soluble tumor necrosis factor (TNF) binding proteins (BP) was investigated in the sera of healthy volunteer blood donors and cancer patients. Two distinct types of TNFBP, types A and B, which are immunologically related to the cellular 75-kD TNF receptor (TNFR) and the cellular 55-kD TNFR, respectively, were assessed by immunoassays using nonblocking anti-receptor antibodies and 125I-recombinant human TNF alpha. As compared to the titers observed in 25 healthy controls, TNFBP types A and B titers were found to be elevated in almost all sera obtained from patients with underlying malignant disease. The highest amounts of TNFBP were seen in the sera of patients with B cell malignancies including hairy cell leukemia (HCL) and type B chronic lymphocytic leukemia. Treatment of HCL patients with recombinant human interferon-alpha was associated with decrease of circulating TNFBP.
在健康志愿者献血者和癌症患者的血清中研究了可溶性肿瘤坏死因子（TNF）结合蛋白（BP）的存在情况。使用非阻断性抗受体抗体和125I重组人TNFα，通过免疫测定法评估了两种不同类型的TNFBP，即A 型和B型，它们分别与细胞75-kD TNF受体（TNFR）和细胞55-kD TNFR在免疫学上相关。与25名健康对照者中观察到的滴度相比，在几乎所有患有潜在恶性疾病患者的血清中，A 型和B型TNFBP滴度均升高。在包括毛细胞白血病（HCL）和B型慢性淋巴细胞白血病在内的B细胞恶性肿瘤患者的血清中，TNFBP含量最高。用重组人干扰素-α治疗HCL患者与循环TNFBP的减少有关。
